Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 11;4(4):e452.
doi: 10.1097/HS9.0000000000000452. eCollection 2020 Aug.

MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease

Inga Hegemann  1 , Clelia Sasselli  1 , Fabio Valeri  2 , Asya Makhro  3   4 , Rouven Müller  1 , Anna Bogdanova  3   4 , Markus G Manz  1 , Max Gassmann  3   4 , Jeroen S Goede  1   4   5
Affiliations

MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease

Inga Hegemann et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design, information on the patients and plasma memantine pharmacokinetics. A. Demographics of the SCD patients and characteristics at enrolment. Sex, age, weight and family origin as well as the corresponding percentage of HbS and HbF measured during the screening period of patients P1-6 are shown. All patients had the HbSS phenotype. ∗number of previous transfusions that applied 9 to 12 months before enrolment. B. Plasma memantine pharmacokinetics during the study periods. The analysis of the memantine concentration in the plasma of the patients revealed a good compliance during the trial with the following exceptions: overdosing by the patient P5 (a) led to psychosis (SAE) and the trial was terminated. Overdosing by P3 (b) and P4 (c) caused reversible increase in plasma memantine levels without discontinuation. Note that the memantine levels found in P6 who stopped the trail at week 5 was within the normal range (not shown). C. Schematic representation of the trial periods. The study was divided into five periods as described in the Supplementary Data. D. Adverse Effects (AE) and Severe Adverse Effects (SAE). The upper part of the table shows the AE and SAE that were attributed to memantine intake, while the lower part reflects the AE and SAE that were considered as not likely related to memantine. ∗Dizziness/vertigo led to a transient dose reduction (10 mg per day for 10 days) that was increased again to 20 mg after cessation of this symptom. ∗∗A pain crisis was defined as ongoing pain lasting for longer than 4 hours (shorter pain periods are defined as “transient pain”) and requiring the application of opiates or treatment at the out patients clinic or emergency department for less than 12 hours.
Figure 2
Figure 2
The impact of memantine on some RBC-related parameters. Means and 95%-CIs of RBC count, Hb, reticulocyte count, lactate dehydrogenase (LDH) activity, ferritin and total bilirubin in plasma as well as percentage of hypochromic and hyperchromic RBC isolated from patients 1 to 4 before enrolment and during the trial are shown. Note that the ferritin values for P4 reach levels around 1500 μg/l and thus are not shown here but appear in Table S2. Screening has no 95%-CI since there is only one measurement. Symbols (dot, ∗,∗∗,∗∗∗ meaning p < 0.1, p < 0.05, p < 0.01, p < 0.001, respectively; values are compared with screening value using Welch t test, not adjusted.). Periods: Pre = pre-screening, Scr = screening, Up = up-titration, Trt = treatment, Dwn = down-titration, Fup = follow-up.
See this image and copyright information in PMC

References

    1. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381:142–151. - PMC - PubMed
    1. Iolascon A, De Franceschi L, Muckenthaler M, et al. EHA research roadmap on hemoglobinopathies and thalassemia: an update. HemaSphere. 2019;3:e208. - PMC - PubMed
    1. McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14:1749–1758. - PMC - PubMed
    1. Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018;379:226–235. - PubMed
    1. Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381:509–519. - PubMed